Tardive dyskinesia and new antipsychotics

  title={Tardive dyskinesia and new antipsychotics},
  author={Christoph U. Correll and Eva M Schenk},
  journal={Current Opinion in Psychiatry},
Purpose of review To provide an update on tardive dyskinesia rates in patients treated with first-generation or second-generation antipsychotics in studies published since the last systematic review in 2004. Recent findings Across 12 trials (n = 28 051, age 39.7 years, 59.7% male, 70.9% white, followed for 463 925 person-years), the annualized tardive dyskinesia incidence was 3.9% for second-generation antipsychotics and 5.5% for first-generation antipsychotics. Stratified by age, annual… 
Tardive Dyskinesia and Tardive Dystonia With Second-Generation Antipsychotics in Non-Elderly Schizophrenic Patients Unexposed to First-Generation Antipsychotics: A Cross-Sectional and Retrospective Study
It is indicated that more clinical attention and research efforts are needed regarding SGA-associated tardive movement syndromes, including a larger-scale prevalence assessment, after the first to indicate that a comorbid obsessive-compulsive syndrome might be an associated factor of tardives movement syndrome.
Incidence of Tardive Dyskinesia with Risperidone or Olanzapine in the Elderly: Results from a 2-Year, Prospective Study in Antipsychotic-Naïve Patients
The TD rates for geriatric patients treated with risperidone and olanzapine were comparable and substantially lower than previously reported for similar patients in direct observation studies using FGAs.
Tardive dyskinesia from atypical antipsychotic agents in patients with mood disorders in a clinical setting.
Tardive dyskinesia and other movement disorders secondary to aripiprazole
The objective of this report is to draw attention to tardive dyskinesia (TD) caused by aripiprazole, a third generation antipsychotic. TD has been traditionally attributed to typical
Covert Dyskinesia With Aripiprazole
Litigation to date suggests that APZ is the atypical antipsychotic most commonly reported with CD, and a possible risk might be APZ's unique mechanism of action and its association with akathisia.
Prevalence of tardive dyskinesia in chronic male inpatients with schizophrenia on long-term clozapine versus typical antipsychotics
There are significant differences in the prevalence and clinical correlates of tardive dyskinesia in schizophrenia treated with clozapine versus typical antipsychotics.
Tardive and spontaneous dyskinesia incidence in the general population
Diabetes, psychoses, and especially schizophrenia are positively associated with SD and TD, with persons with schizophrenia having 4.4 times greater risk of SD than those without the disease.
Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients
This review will discuss the evidence for a number of medications of several different classes that have been studied for the treatment of TD since the 1970s with an emphasis on placebo controlled trials when possible and suggest the use of atypical versus conventional antipsychotics whenever possible.
[Tardive dyskinesia in patients with schizophrenia treated with olanzapine - results from a 20-month, prospective, open study under naturalistic conditions].
The study demonstrated high prevalence of tardive dyskinesia, and the annual incidence comparable to the results of a meta-analysis by Corell et al., and the use of antipsychotics in polytherapy more than tripled the risk of tARDive dysKinesia.
Tardive Dyskinesia: Treatment Update
Tardive dyskinesia (TD) is caused by exposure to medications with dopamine antagonism, mainly antipsychotics. It often distresses individuals, physically and emotionally and affects their quality of


The effect of atypical versus typical antipsychotics on tardive dyskinesia
  • J. Leon
  • Psychology, Medicine
    European Archives of Psychiatry and Clinical Neuroscience
  • 2006
This study raises the question that new TD studies need to establish whether decades of treatment with atypical antipsychotics make a difference, and naturalistic design, relatively small samples in the first two groups, and lack of information on the duration of the atypicals.
The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study.
  • J. de Leon
  • Psychology, Medicine
    European archives of psychiatry and clinical neuroscience
  • 2007
This study raises the question that new TD studies need to establish whether decades of treatment with atypical antipsychotics make a difference, and the lack of information on the duration of the atypicals and their relatively recent introduction to the market.
Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients.
The risk of tardive dyskinesia in older outpatients is high, even with relatively short treatment with low doses of conventional neuroleptics.
Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course
The findings support the view that tardive dyskinesia is a dynamic phenomenon, is only partly drug-induced, has a mild course during treatment with modern neuroleptics, and appears to have some correlation with mental slowness.
Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.
Patients in the first 5 years of exposure to persistent TD could be targeted for prevention programs if resources are limited and differences in incidence across studies may be explained in terms of patient characteristics and other methodological factors.
Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.
Use of higher amounts of neuroleptics, particularly high-potency ones, should be avoided in older patients, patients with alcohol abuse/dependence, or patients with a subtle movement disorder at baseline; these patients are at a higher risk of developing TD.
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.
Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies.
The conclusion of the meta-analysis was that tardive dyskinesia must be considered a weak risk factor in terms of mortality.
Extrapyramidal side effects with atypical neuroleptics in bipolar disorder